A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies

Samonis, George; Vardakas, Konstantinos Z.; Maraki, Sofia; Tansarli, Giannoula S.; Dimopoulou, Dimitra; Kofteridis, Diamantis P.; Andrianaki, Angeliki M.; Falagas, Matthew E.

doi:10.1007/s00520-013-1816-5

Cited by 45 publications

(44 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study there was a predominance of Gram-negative bacteria among hematology-oncology patients with HAIs, as has been reported in other studies [12,26,45]. This might be due to the use of less cytotoxic chemotherapy that includes less severe mucositis and less profound neutropenia or the failure to perform routine prophylaxis against Gram-negative bacteria [46][47][48][49].…”

Section: Citationsupporting

confidence: 80%

“…The estimated incidence density of healthcare-associated infections (HAIs) ranges from 11 to 21.8 per 1,000 patients-days [5][6][7]. The attributable length of stay to HAIs has been found to vary from 6.8 to 11.5 days, the attributable mortality from 4.9% to 26.3%and the attributable cost from £6,324 (Canadian dollar) to £19,110 (US dollar) per oncology patient with HAI [8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Surveillance of Healthcare-Associated Infections Rates in Hematology-Oncology Patients

Kafazi¹,

Stylianou²,

Zwmas³

et al. 2017

J Integr Oncol

View full text Add to dashboard Cite

show abstract

Section: Citationsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Surveillance of Healthcare-Associated Infections Rates in Hematology-Oncology Patients

Kafazi¹,

Stylianou²,

Zwmas³

et al. 2017

J Integr Oncol

View full text Add to dashboard Cite

show abstract

“…29 However, this tendency has reversed again, with GN bacteria becoming more frequent than GP in many centers. [32][33][34][35][36][37][38] According to a questionnaire survey performed among hematology centers from Europe and Israel participating in the European Conference on Infections in Leukemia (ECIL) in 2011, Enterobacteriaceae were isolated in approximately 30% (range 8-56%) of the BSIs, followed by coagulase-negative staphylococci (24%, range 7-51%). 39 The GP to GN ratio was 55% to 45%, but a large variability between hospitals and countries has been noted.…”

Section: Increase In Gram-negativesmentioning

confidence: 99%

Bloodstream infections in neutropenic cancer patients: A practical update

2016

View full text Add to dashboard Cite

Bloodstream infections (BSI) are among the most frequent complications in neutropenic cancer patients and, if caused by Gram-negative rods, are associated with high mortality. Thus, fever during neutropenia warrants prompt empirical antibiotic therapy which should be active against the most frequent Gram-negatives. In the last decade, there has been a worldwide increase in multidrug resistant (MDR) strains. In these cases, the traditional choices such as oral therapy, ceftazidime, cefepime, piperacillin-tazobactam, or even carbapenems, might be ineffective. Therefore novel deescalation approach has been proposed for patients who are at high risk for infections due to MDR bacteria. It consists of starting antibiotics which cover the most probable resistant strain but it is narrowed down after 72 hours if no MDR pathogen is isolated. With increasing bacterial resistance, the benefit of fluoroquinolone prophylaxis during prolonged neutropenia remains to be confirmed. Antibiotic stewardship and infection control programs are mandatory in every cancer center.

show abstract

“…[4][5][6] Other studies have analyzed hematologic and solid tumor patients together, thus creating groups that are too heterogeneous to be analyzed properly. 4,[7][8][9][10][11] In this review we focus on the recent literature regarding the incidence, epidemiology, clinical features, etiology, antimicrobial resistance, and outcomes of BSI of adult cancer patients with solid tumors. To this end, we conducted a comprehensive literature search in the PubMed/MEDLINE database, using the following search terms: bloodstream infection, bacteremia, cancer, solid tumor, solid neoplasm, solid malignancy, adults, neutropenia, epidemiology, etiology, causative agents, antimicrobial resistance, outcome, mortality, and case-fatality.…”

Section: Introductionmentioning

confidence: 99%

Bloodstream infections in patients with solid tumors

2016

View full text Add to dashboard Cite

Little information is currently available regarding bloodstream infection (BSI) in patients with solid tumors who, for a variety of reasons, are particularly predisposed to develop this condition. In this review we focus on the incidence, epidemiology, clinical features, etiology, antimicrobial resistance, and outcomes of BSI of adult cancer patients with solid tumors. Most episodes of BSI occur in nonneutropenic patients, in whom the site of primary or metastatic tumor often serves as the portal of entry. The urinary tract and the abdomen are the most frequent sources of infection, and cholangitis is the most common recurrent source of BSI. Gram-negative bacilli are becoming the leading cause of BSI in patients with solid tumors, and the rate of multidrug resistance is increasingly being recognized. The case-fatality rate in patients with solid tumors and BSI is high, especially among those with comorbidities, advanced neoplasms, corticosteroid therapy, and shock at presentation.

show abstract

A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies

Abstract: Gram-negative bacteria were the predominantly isolated pathogens from patients with cancer in our population. The overall mortality remains high.

Cited by 45 publications

References 33 publications

Surveillance of Healthcare-Associated Infections Rates in Hematology-Oncology Patients

Surveillance of Healthcare-Associated Infections Rates in Hematology-Oncology Patients

Bloodstream infections in neutropenic cancer patients: A practical update

Bloodstream infections in patients with solid tumors

Contact Info

Product

Resources

About